Eli Lilly And Stock Working Capital
LLY Stock | USD 726.31 19.64 2.63% |
Eli Lilly and fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.
Eli |
Eli Lilly and Company Working Capital Analysis
Eli Lilly's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Eli Lilly Working Capital | (1.57 B) |
Most of Eli Lilly's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eli Lilly and is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition |
Based on the company's disclosures, Eli Lilly and has a Working Capital of (1.57 Billion). This is 467.95% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The working capital for all United States stocks is significantly higher than that of the company.
Eli Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eli Lilly's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eli Lilly could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics of similar companies.Eli Lilly is currently under evaluation in working capital category among related companies.
Eli Fundamentals
Return On Equity | 0.48 | ||||
Return On Asset | 0.12 | ||||
Profit Margin | 0.15 % | ||||
Operating Margin | 0.34 % | ||||
Current Valuation | 695 B | ||||
Shares Outstanding | 950.77 M | ||||
Shares Owned By Insiders | 0.16 % | ||||
Shares Owned By Institutions | 84.31 % | ||||
Number Of Shares Shorted | 5.42 M | ||||
Price To Earning | 54.92 X | ||||
Price To Book | 66.34 X | ||||
Price To Sales | 20.94 X | ||||
Revenue | 34.12 B | ||||
Gross Profit | 21.91 B | ||||
EBITDA | 12.46 B | ||||
Net Income | 5.24 B | ||||
Cash And Equivalents | 2.07 B | ||||
Cash Per Share | 2.97 X | ||||
Total Debt | 25.23 B | ||||
Debt To Equity | 1.58 % | ||||
Current Ratio | 1.13 X | ||||
Book Value Per Share | 11.98 X | ||||
Cash Flow From Operations | 4.24 B | ||||
Short Ratio | 1.82 X | ||||
Earnings Per Share | 5.78 X | ||||
Price To Earnings To Growth | 1.43 X | ||||
Target Price | 826.94 | ||||
Number Of Employees | 43 K | ||||
Beta | 0.37 | ||||
Market Capitalization | 709.22 B | ||||
Total Asset | 64.01 B | ||||
Retained Earnings | 10.31 B | ||||
Working Capital | (1.57 B) | ||||
Current Asset | 12.57 B | ||||
Current Liabilities | 8.23 B | ||||
Annual Yield | 0.01 % | ||||
Five Year Return | 1.83 % | ||||
Net Asset | 64.01 B | ||||
Last Dividend Paid | 4.52 |
About Eli Lilly Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eli Lilly in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eli Lilly's short interest history, or implied volatility extrapolated from Eli Lilly options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Eli Lilly Piotroski F Score and Eli Lilly Altman Z Score analysis. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.